TGF-β blockers combined with anti-PD-L1 antibodies inhibit TGF-β signal transduction in CAFs, which facilitates the infiltration of T cells into cancer nests and stimulates effective anti-tumor immunity (64–66). This evidence concerns the gene TGFB1 and cancer.